Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

Relapsed or Refractory T-cell lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Best Price Guarantee Length Publisher Published Date SKU
from $10,500 218 Pages Thelansis Knowledge Partners December, 2021 THKP17066450
Best Price Guarantee
Price from $10,500
Length 218 Pages
Publisher Thelansis Knowledge Partners
Published Date December, 2021
SKU THKP17066450

Relapsed or Refractory T-cell lymphoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Relapsed or Refractory T-cell lymphoma Disease overview, pathogenesis, identified and emerging biomarkers, pipeline assessment, competitive landscape, KOLs perspective, Clinical Trial Landscaping, Probable launch date estimation Regulatory framework, Epidemiology; Incidence, Prevalence, and current therapy market share, Order of entry, patient share, Market uptake, Peak patient share, Disease burden, Annual cost of therapy, the market forecast for the USA, Germany, France, Italy, Spain, UK, Japan and China 2020 to 2030


1. Relapsed or Refractory T-cell lymphoma – Key Findings Summary
1.1. Clinical findings
1.1.1. Disease overview
1.1.2. Therapeutic practices
1.1.3. Future outlook
1.2. Commercial findings
1.2.1. Relapsed or Refractory T-cell lymphoma market scenario 2020
1.2.2. Relapsed or Refractory T-cell lymphoma market scenario 2025
1.2.3. Relapsed or Refractory T-cell lymphoma market scenario 2030
2. Relapsed or Refractory T-cell lymphoma Overview
2.1. Disease Introduction
2.2. Pathophysiology
2.3. Signs and Symptoms
2.4. Risk Factors
2.5. Etiology
2.6. Classification
2.7. Pathogenesis
2.8. Diagnosis
2.9. Complications
2.10. Treatment Algorithm
2.10.1. Treatment in US (guidelines)
2.10.2. Treatment in EU-5 (guidelines)
2.10.3. Treatment in Japan (guidelines)
2.10.4. Treatment in China (guidelines)
2.11. Treatment Goals for Relapsed or Refractory T-cell lymphoma
2.12. Referral Patterns
2.12.1. Referral Scenario in US
2.12.2. Referral Scenario in EU-5
2.12.3. Referral Scenario in Japan
2.12.4. Referral Scenario in China
2.13.Relapsed or Refractory T-cell lymphoma Prognosis
2.14.Healthcare burden
2.14.1. Healthcare burden in US
2.14.2. Healthcare burden in EU-5
2.14.3. Healthcare burden in Japan
2.14.4. Healthcare burden in China
2.15. Unmet Needs in Relapsed or Refractory T-cell lymphoma management
2.16. Market Opportunity for Relapsed or Refractory T-cell lymphoma
2.17. KOL Comments on current and upcoming/expected treatment practices in Relapsed or Refractory T-cell lymphoma
3. Epidemiology
3.1. Epidemiology Overview
3.2. Epidemiology by Geography
3.2.1. Relapsed or Refractory T-cell lymphoma Epidemiology in US (2019-2030)
3.2.1.1. Incidence of Relapsed or Refractory T-cell lymphoma
3.2.1.2. Diagnosed cases
3.2.1.3. Treatable Patient Pool
3.2.1.4. Epidemiology Trends
3.2.2. Relapsed or Refractory T-cell lymphoma Epidemiology in EU-5 (2019-2030)
3.2.2.1. Incidence of Relapsed or Refractory T-cell lymphoma
3.2.2.2. Diagnosed cases
3.2.2.3. Treatable Patient Pool
3.2.2.4. Epidemiology Trends
3.2.3. Relapsed or Refractory T-cell lymphoma Epidemiology in Japan (2019-2030)
3.2.3.1. Incidence of Relapsed or Refractory T-cell lymphoma
3.2.3.2. Diagnosed cases
3.2.3.3. Treatable Patient Pool
3.2.3.4. Epidemiology Trends
3.2.4. Relapsed or Refractory T-cell lymphoma Epidemiology in China (2019-2030)
3.2.4.1. Incidence of Relapsed or Refractory T-cell lymphoma
3.2.4.2. Diagnosed cases
3.2.4.3. Treatable Patient Pool
3.2.4.4. Epidemiology Trends
3.3. Epidemiology Trends (World-wide)
4. Market Outlook
4.1. US Relapsed or Refractory T-cell lymphoma Market Forecast 2019-2030
4.1.1. Market Progression (Futuristic)
4.1.2. Market Trends and Expectations
4.1.2.1. Worst case scenario
4.1.2.2. Base Case Scenario
4.1.2.3. Best Case Scenario
4.1.3. Drivers and Barriers
4.2. UK Relapsed or Refractory T-cell lymphoma Market Forecast 2019-2030
4.2.1. Market Progression (Futuristic)
4.2.2. Market Trends and Expectations
4.2.2.1. Worst case scenario
4.2.2.2. Base Case Scenario
4.2.2.3. Best Case Scenario
4.2.3. Drivers and Barriers
4.3. France Relapsed or Refractory T-cell lymphoma Market Forecast 2019-2030
4.3.1. Market Progression (Futuristic)
4.3.2. Market Trends and Expectations
4.3.2.1. Worst case scenario
4.3.2.2. Base Case Scenario
4.3.2.3. Best Case Scenario
4.3.3. Drivers and Barriers
4.4. Germany Relapsed or Refractory T-cell lymphoma Market Forecast 2019-2030
4.4.1. Market Progression (Futuristic)
4.4.2. Market Trends and Expectations
4.4.2.1. Worst case scenario
4.4.2.2. Base Case Scenario
4.4.2.3. Best Case Scenario
4.4.3. Drivers and Barriers
4.5. Italy Relapsed or Refractory T-cell lymphoma Market Forecast 2019-2030
4.5.1. Market Progression (Futuristic)
4.5.2. Market Trends and Expectations
4.5.2.1. Worst case scenario
4.5.2.2. Base Case Scenario
4.5.2.3. Best Case Scenario
4.5.3. Drivers and Barriers
4.6. Spain Relapsed or Refractory T-cell lymphoma Market Forecast 2019-2030
4.6.1. Market Progression (Futuristic)
4.6.2. Market Trends and Expectations
4.6.2.1. Worst case scenario
4.6.2.2. Base Case Scenario
4.6.2.3. Best Case Scenario
4.6.3. Drivers and Barriers
4.7. Japan Relapsed or Refractory T-cell lymphoma Market Forecast 2019-2030
4.7.1. Market Progression (Futuristic)
4.7.2. Market Trends and Expectations
4.7.2.1. Worst case scenario
4.7.2.2. Base Case Scenario
4.7.2.3. Best Case Scenario
4.7.3. Drivers and Barriers
4.8. China Relapsed or Refractory T-cell lymphoma Market Forecast 2019-2030
4.8.1. Market Progression (Futuristic)
4.8.2. Market Trends and Expectations
4.8.2.1. Worst case scenario
4.8.2.2. Base Case Scenario
4.8.2.3. Best Case Scenario
4.8.3. Drivers and Barriers
4.9. Key Expected Milestones (world-wide) Impacting the Market
5. Competitive Landscape
5.1. Pipeline Therapies Overview
5.1.1. Phase III Therapies
5.1.1.1. Current Status
5.1.1.2. Trial details, results
5.1.1.3. Approval Timeline
5.1.1.4. Likelihood of approval
5.1.1.5. Expected Product Positioning
5.1.1.2. All other Phase III Therapies …..
5.1.1.3. Attribute Analysis of Phase III molecules
5.1.2. Phase II and Phase I/II Therapies
5.1.2.1. Current Status
5.1.2.2. Trial details, results
5.1.2.3. Approval Timelines
5.1.3. List of active Pre-clinical Therapies
5.1.3.1. Status in Relapsed or Refractory T-cell lymphoma
5.1.3.2. Company positioning
5.1.3.2. All other pre-clinical therapies
5.1.4. List of Inactive/discontinued assets
5.1.4.1. Business impact of discontinuations on current pipeline
5.1.5. Potential winners from Relapsed or Refractory T-cell lymphoma Pipeline
5.1.5.1. Potential Blockbusters across the pipeline
6. Regulatory/Approval Scenario
6.1. Regulatory/Approval Framework in US
6.1.1. Policy Framework
6.1.2. Payer Expectations
6.2. Regulatory/Approval Framework in UK
6.2.1. Policy Framework
6.2.2. Payer Expectations
6.3. Regulatory/Approval Framework in France
6.3.1. Policy Framework
6.3.2. Payer Expectations
6.4. Regulatory/Approval Framework in Germany
6.4.1. Policy Framework
6.4.2. Payer Expectations
6.5. Regulatory/Approval Framework in Italy
6.5.1. Policy Framework
6.5.2. Payer Expectations
6.6. Regulatory/Approval Framework in Spain
6.6.1. Policy Framework
6.6.2. Payer Expectations
6.7. Regulatory/Approval Framework in Japan
6.7.1. Policy Framework
6.7.2. Payer Expectations
6.8. Regulatory/Approval Framework in China
6.8.1. Policy Framework
6.8.2. Payer Expectations
7. Clinical Trial Assessment – Current and Future Paradigm
7.1. Distribution of Primary Endpoints across trials
7.2. Distribution of Secondary Endpoints across trials
7.3. Evolution and acceptance of surrogate endpoints
7.4. Key Investigator initiated trials
7.5. Attrition analysis
7.5.1. Suspended/Discontinued Assets
7.5.2. Failed Trials, Reasons and Business Impact
7.5.3. Terminated Trials, Reasons and Business Impact
7.5.4. Withdrawn Trials, Reasons and Business Impact
7.6. Trial enrollment scenario and challenges
7.7. Clinical Trial Guidance (across geographies)
8. Thelansis Commentary
8.1. Key Unmet needs in Relapsed or Refractory T-cell lymphoma
8.2. Possible Best-case Clinical Trial Strategies
8.3. Possible Best Case Targeted Product Profile (TPP)
8.4. Possible Best-case Market positioning strategies
8.5. Possible Best-case Market Access Strategies
8.6. Possible Best-case LCM Strategies
8.7. Overall View on Relapsed or Refractory T-cell lymphoma Market in Dollar Value
9. Report Methodology
9.1. Secondary research
9.2. Primary research
9.3. Data collation
9.4. Insight Generation
10. About Thelansis
10.1. Our Capabilities
10.2. Our Services
10.3. Our Contacts
10.4. Disclaimer

$10,500
$16,500

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings